AU2014217892B2 - Design of short oligonucleotides as vaccine adjuvants and therapeutic agents - Google Patents

Design of short oligonucleotides as vaccine adjuvants and therapeutic agents Download PDF

Info

Publication number
AU2014217892B2
AU2014217892B2 AU2014217892A AU2014217892A AU2014217892B2 AU 2014217892 B2 AU2014217892 B2 AU 2014217892B2 AU 2014217892 A AU2014217892 A AU 2014217892A AU 2014217892 A AU2014217892 A AU 2014217892A AU 2014217892 B2 AU2014217892 B2 AU 2014217892B2
Authority
AU
Australia
Prior art keywords
alkyl
aryl
compound
independently
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2014217892A
Other languages
English (en)
Other versions
AU2014217892A1 (en
Inventor
Radhakrishnan P. Iyer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Star Therapeutics Inc
Original Assignee
Spring Bank Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Spring Bank Pharmaceuticals Inc filed Critical Spring Bank Pharmaceuticals Inc
Publication of AU2014217892A1 publication Critical patent/AU2014217892A1/en
Application granted granted Critical
Publication of AU2014217892B2 publication Critical patent/AU2014217892B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
AU2014217892A 2013-02-18 2014-02-18 Design of short oligonucleotides as vaccine adjuvants and therapeutic agents Ceased AU2014217892B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361766011P 2013-02-18 2013-02-18
US61/766,011 2013-02-18
PCT/US2014/016996 WO2014127378A2 (en) 2013-02-18 2014-02-18 Design of short oligonucleotides as vaccine adjuvants and therapeutic agents

Publications (2)

Publication Number Publication Date
AU2014217892A1 AU2014217892A1 (en) 2015-08-13
AU2014217892B2 true AU2014217892B2 (en) 2018-11-22

Family

ID=51354704

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014217892A Ceased AU2014217892B2 (en) 2013-02-18 2014-02-18 Design of short oligonucleotides as vaccine adjuvants and therapeutic agents

Country Status (8)

Country Link
US (1) US10391166B2 (enExample)
EP (1) EP2956145A4 (enExample)
JP (2) JP6502267B2 (enExample)
KR (1) KR20150119924A (enExample)
CN (1) CN105992587A (enExample)
AU (1) AU2014217892B2 (enExample)
CA (1) CA2899599A1 (enExample)
WO (1) WO2014127378A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2991156A1 (en) * 2015-07-02 2017-01-05 Spring Bank Pharmaceuticals, Inc. Compositions and methods for the treatment of viral infection
TW201717968A (zh) * 2015-07-14 2017-06-01 春季銀行製藥公司 誘導ｒｉｇ－ｉ和其他模式辨識受體之化合物及組成物
SG11201900154VA (en) * 2016-07-15 2019-02-27 Sperovie Biosciences Inc Compounds, compositions, and methods for the treatment of disease
WO2018013887A1 (en) * 2016-07-15 2018-01-18 Sperovie Biosciences, Inc. Compounds, compositions, and methods for the treatment of disease
EP3675859A4 (en) * 2017-08-31 2021-06-30 Sperovie Biosciences, Inc. COMPOUNDS, COMPOSITIONS AND PROCEDURES FOR TREATMENT OF DISEASES
SG11202001498QA (en) * 2017-09-05 2020-03-30 Blackthorn Therapeutics Inc Vasopressin receptor antagonists and products and methods related thereto
WO2019051488A1 (en) 2017-09-11 2019-03-14 Sperovie Biosciences, Inc. COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISEASE
US11707531B2 (en) 2017-09-11 2023-07-25 F-star Therapeutics, Inc. Compounds, compositions, and methods for the treatment of disease
JP2021523127A (ja) * 2018-05-04 2021-09-02 ユービーアイ アイピー ホールディングスＵｂｉ Ｉｐ Ｈｏｌｄｉｎｇｓ 限られたｔ細胞炎症反応で標的抗体産生を促進する人工的な無差別ｔヘルパー細胞エピトープ
EP4023244A4 (en) * 2019-08-28 2023-11-01 NA Vaccine Institute INFLUENZA VACCINE COMPOSITION BASED ON A NEW NUCLEIC ACID
WO2021046426A1 (en) * 2019-09-06 2021-03-11 Sperovie Biosciences, Inc. Cyclic dinucleotide sting agonists tethered to a pd-1 or ctla-4 antibodies

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012030626A2 (en) * 2010-08-30 2012-03-08 Spring Bank Pharmaceuticals, Inc. Design of oligonucleotide analogs as therapeutic agents

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8076303B2 (en) * 2005-12-13 2011-12-13 Spring Bank Pharmaceuticals, Inc. Nucleotide and oligonucleotide prodrugs
US20080161324A1 (en) * 2006-09-14 2008-07-03 Johansen Lisa M Compositions and methods for treatment of viral diseases
KR101806314B1 (ko) * 2008-04-03 2017-12-07 스프링 뱅크 파마슈티칼스, 인크. 바이러스 감염증을 치료하기 위한 조성물 및 방법

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012030626A2 (en) * 2010-08-30 2012-03-08 Spring Bank Pharmaceuticals, Inc. Design of oligonucleotide analogs as therapeutic agents

Also Published As

Publication number Publication date
AU2014217892A1 (en) 2015-08-13
WO2014127378A8 (en) 2014-10-02
JP2018087243A (ja) 2018-06-07
CA2899599A1 (en) 2014-08-21
KR20150119924A (ko) 2015-10-26
CN105992587A (zh) 2016-10-05
EP2956145A2 (en) 2015-12-23
EP2956145A4 (en) 2016-08-17
US20150374816A1 (en) 2015-12-31
US10391166B2 (en) 2019-08-27
JP2016513113A (ja) 2016-05-12
JP6502267B2 (ja) 2019-04-17
WO2014127378A2 (en) 2014-08-21

Similar Documents

Publication Publication Date Title
US10391166B2 (en) Short oligonucleotides as vaccine adjuvants and therapeutic agents
US9040234B2 (en) Oligonucleotide analogs as therapeutic agents
KR101620394B1 (ko) 바이러스 감염증을 치료하기 위한 조성물 및 방법
CN1257912C (zh) 用于治疗乙型肝炎的β－L－2′－脱氧－核苷
US9085599B2 (en) 2′allene-substituted nucleoside derivatives
US20210277403A1 (en) Methods and compositions for targeting pd-l1
TW202400185A (zh) 用於治療病毒感染的化合物及方法
HK1229263A1 (en) Design of short oligonucleotides as vaccine adjuvants and therapeutic agents
HK1229263A (en) Design of short oligonucleotides as vaccine adjuvants and therapeutic agents
TW202604551A (zh) 用於治療ｂ型肝炎病毒之經修飾之反義寡核苷酸
CN1911237A (zh) 用于治疗乙型肝炎的β－L－2＇－脱氧－核苷
HK1198516B (en) Compositions and methods for treating viral infections

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired